Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DDCI-01 in Men With BPH-LUTS and ED
CTR20233686Phase 2Completed
- Sponsor
- Chongqing Dikang Erle Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DDCI-01 in benign prostatic hyperplasia (BPH), Micturition disorder, erectile dysfunction (ED), sponsored by Chongqing Dikang Erle Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
DDCI-01
03
Conditions
benign prostatic hyperplasia (BPH)Micturition disordererectile dysfunction (ED)
Beyond the preview
Go deeper on CTR20233686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233686.